Content
All Posts > Content under Healthcare
Revive Initiates Bucillamine Phase 2 Study, Expands Focus To Include Cannabinoid Research
Article By:
Jason Napodano
Read
Tuesday, February 7, 2017 10:27 AM EDT
Revive Therapeutics would likely improve over the next few years by advancing its pipeline and expanding efforts into cannabinoid research.
In this article: RVVTF
Can Gilead Cure The Earnings Season Blues?
Article By:
Leigh Drogen
Read
Tuesday, February 7, 2017 9:24 AM EDT
For Gilead Sciences, Inc., we are calling for earnings of $2.50 per share on $7.21 billion in revenue, about 7 cents higher than the Street on the bottom line and $30 million on the top.
In this article: GILD
PETX Down Today, But Not Out
Article By:
Gary Berman
Read
Monday, February 6, 2017 4:16 PM EDT
PETX: The FIBOCALL view
In this article: PETX
Q4 Earnings Faring Well For Pharma ETFs
Article By:
Sweta Killa
Read
Monday, February 6, 2017 12:51 PM EDT
The Q4 earnings season is faring better than the last few years with not only earnings growth on track to reach the highest level in two years but also total earnings set to create a new quarterly record.
MediWound Receives Permission To Expand Study Population Scope
Article By:
KKD Healthcare Analytics
Read
Monday, February 6, 2017 11:21 AM EDT
MediWound announced that it has been granted that it has received an endorsement from The European Medicines Agency for expanding the patient population in Phase 3 Children Innovative Debridement Study.
In this article: MDWD
BioSig's Targets Enormous A-Fib Market With Game-Changing Device
Article By:
Jason Napodano
Read
Monday, February 6, 2017 10:55 AM EDT
US markets have done well since the election, especially our un-regulated Financials (what could possibly go wrong?), who jumped 18.66% through Friday.
In this article: BSGM
Bullish Days Ahead For Military Companies?
Article By:
Vivian Lewis
Read
Sunday, February 5, 2017 2:19 PM EDT
UK firm BAE Systerms may gain billions from a repair contract worth $1.4 trillion given to Britain and Australian firms for repairing and replacing parts for the F-35 stealth fighter.
JPM: "Turning Points In Market Trends Are Occurring At The Fastest Pace In History"
Article By:
Tyler Durden
Read
Sunday, February 5, 2017 3:17 AM EDT
Stocks are reacting quickly to news, which leaves human investors less time to act. An example is earnings announcements where stocks immediately adjust to a price level and there is very little post-earnings drift.
In this article: JNJ
Besides Interest Rates, Here's Why REIT Investments Seem Risky
Article By:
Zacks Investment Research
Read
Saturday, February 4, 2017 7:29 PM EDT
Indications from Fed officials on raising the key interest rate multiple times over the next two years have spread jitters in the REIT industry. The bond rout has also added to its woes.
Week In Review: China To Add 300 Drugs To National Reimbursement Drug List
Article By:
ChinaBio® Today
Read
Saturday, February 4, 2017 1:21 PM EDT
According to sources, China is getting close to announcing a revised National Reimbursement Drug List, the group of drugs covered by China's national insurance plan. 130 will be chemical drugs and the rest will be traditional Chinese medicines.
My Recent Stock Purchase: Pfizer
Article By:
Dividend Diplomats
Read
Saturday, February 4, 2017 11:13 AM EDT
As dividend investors, we need to sit tight and buy when we find the right value at hopefully the right times if you can. This purchase signifies that, based on my analysis.
In this article: PFE
Trump + Stocks: The Week In Review - Friday, Feb. 3
Article By:
The Fly
Read
Friday, February 3, 2017 6:33 PM EDT
For most of the week, President Trump's executive order regarding immigration made headlines, but on Friday, the President signed a new executive order dramatically scaling back Dodd-Frank, after meeting with top executives from major companies.
In this article: SBUX, AAPL, MSFT, NFLX, TSLA, IBM, GS, DAL, GM, F, NVS, MRK, JNJ, CELG, LLY, AMGN, PTLA, ITCI, BX, WFC, BAC, MS, C